Search

Displaying results 3151 - 3160 of 5451 in total
  1. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    It is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.

  2. Drug

    Medifoxamine

    go.drugbank.com/drugs/DB13219
    Approved

    Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity

  3. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.

  4. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

    Products: CIPROFLOXACINO TABLETAS RECUBIERTAS 500 MG.
  5. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.

    Products: MIVACRON INJECTION 10 mg/5 ml, Mivacron 2 mg/ml - Injektionslösung
  6. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

    Products: VELETRI® 1.5 MG, VELETRI®0.5 MG
  7. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  8. Drug

    Oxymetazoline

    go.drugbank.com/drugs/DB00935
    ApprovedInvestigational

    [L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment

    Synonyms: 6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenolProducts: OXIFREE®0.25 MG/ ML, OXIMETAZOLINA 0.5 MG/1 ML. SOLUCION NASAL
  9. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. … While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease.

    Mixtures: INSUMAN COMB 25 100I E/ML, INSUMAN COMB 25 100I E/ML
  10. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.